Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Cadet, Jean Lud ^a   McCoy, Michael T ^a   Cai, Ning Sheng ^a   Krasnova, Irina N ^a   Ladenheim, Bruce ^a   Beauvais, Genevieve ^a   Wilson, Natascha ^a   Wood III, William ^b   Becker, Kevin G ^b   Hodges, Amber B ^a,c  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MORGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE 1; HEAT SHOCK PROTEIN 27; HEME OXYGENASE 1; METHAMPHETAMINE; PROTEIN C FOS; PROTIRELIN; CENTRAL STIMULANT AGENT; DOPAMINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GENE EXPRESSION; GENETIC REGULATION; MALE; MESENCEPHALON; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RAT; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; ANIMAL; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ANIMALIA; MAMMALIA; RATTUS;

ANIMALS; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MESENCEPHALON; METHAMPHETAMINE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEROTONIN;

EID: 70649101373     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007812     Document Type: Article

References (128)

1. Kramer JC, Fischman VS, Littlefield DC (1967) Amphetamine abuse. Pattern and effects of high doses taken intravenously. Jama 201: 305-309.
2. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60: 379-407.
3. Gold MS, Kobeissy FH, Wang KK, Merlo LJ, Bruijnzeel AW, et al. (2009) Methamphetamine- and trauma-induced brain injuries: comparative cellular and molecular neurobiological substrates. Biol Psychiatry 66: 118-127.
4. Simon SL, Domier CP, Sim T, Richardson K, Rawson RA, et al. (2002) Cognitive performance of current methamphetamine and cocaine abusers. J Addict Dis 21: 61-74.
5. Chang L, Alicata D, Ernst T, Volkow N (2007) Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 Suppl 1: 16-32.
6. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, et al. (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28: 5756-5761.
7. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382.
8. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, et al. (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63: 90-100.
9. Friedman SD, Castaneda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61: 35-44.
10. Seiden LS, Fischman MW, Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1: 215-219.
11. Bardsley ME, Bachelard HS (1981) Catecholamine levels and tyrosine hydroxylase activities in rat brain regions after chronic treatment with, and withdrawal of, methamphetamine. Biochem Pharmacol 30: 1543-1549.
12. Graham DL, Noailles PA, Cadet JL (2008) Differential neurochemical consequences of an escalating dose-binge regimen followed by single-day multiple-dose methamphetamine challenges. J Neurochem 105: 1873-1885.
13. Jayanthi S, Deng X, Ladenheim B, McCoy MT, Cluster A, et al. (2005) Calcineurin/NFAT-induced up-regulation of the Fas ligand/Fas death pathway is involved in methamphetamine-induced neuronal apoptosis. Proc Natl Acad Sci U S A 102: 868-873.
14. Wagner GC, Seiden LS, Schuster CR (1979) Methamphetamine-induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend 4: 435-438.
15. Cadet JL, Jayanthi S, Deng X (2003) Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. Faseb J 17: 1775-1788.
16. Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, et al. (2007) Persistence of tolerance to methamphetamine-induced monoamine deficits. Eur J Pharmacol 559: 46-54.
17. Johnson-Davis KL, Fleckenstein AE, Wilkins DG (2003) The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482: 151-154.
18. Cadet JL, Krasnova IN, Ladenheim B, Cai NS, McCoy MT, et al. (2009) Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain. Neurotox Res 15: 252-259.
19. Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG (2004) Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 309: 578-586.
20. Thomas DM, Kuhn DM (2005) Attenuated microglial activation mediates tolerance to the neurotoxic effects of methamphetamine. J Neurochem 92: 790-797.
21. Calabrese EJ (2008) Converging concepts: adaptive response, preconditioning, and the Yerkes-Dodson Law are manifestations of hormesis. Ageing Res Rev 7: 8-20.
22. Dhodda VK, Sailor KA, Bowen KK, Vemuganti R (2004) Putative endogenous mediators of preconditioning-induced ischemic tolerance in rat brain identified by genomic and proteomic analysis. J Neurochem 89: 73-89.
23. Dirnagl U, Simon RP, Hallenbeck JM (2003) Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26: 248-254.
24. Koerner IP, Gatting M, Noppens R, Kempski O, Brambrink AM (2007) Induction of cerebral ischemic tolerance by erythromycin preconditioning reprograms the transcriptional response to ischemia and suppresses inflammation. Anesthesiology 106: 538-547.
25. Stenzel-Poore MP, Stevens SL, King JS, Simon RP (2007) Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis. Stroke 38: 680-685.
26. Stenzel-Poore MP, Stevens SL, Xiong Z, Lessov NS, Harrington CA, et al. (2003) Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet 362: 1028-1037.
27. Wang L, Traystman RJ, Murphy SJ (2008) Inhalational anesthetics as preconditioning agents in ischemic brain. Curr Opin Pharmacol 8: 104-110.
28. Guo L, Lobenhofer EK, Wang C, Shippy R, Harris SC, et al. (2006) Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol 24: 1162-1169.
29. Zhou T, Chou J, Watkins PB, Kaufmann WK (2009) Toxicogenomics: transcription profiling for toxicology assessment. Exs 99: 325-366.
30. Burre J, Volknandt W (2007) The synaptic vesicle proteome. J Neurochem 101: 1448-1462.
31. Cadet JL, Jayanthi S, McCoy MT, Vawter M, Ladenheim B (2001) Temporal profiling of methamphetamine-induced changes in gene expression in the mouse brain: evidence from cDNA array. Synapse 41: 40-48.
32. Cadet JL, McCoy MT, Ladenheim B (2002) Distinct gene expression signatures in the striata of wild-type and heterozygous c-fos knockout mice following methamphetamine administration: evidence from cDNA array analyses. Synapse 44: 211-226.
33. Jayanthi S, McCoy MT, Beauvais G, Ladenheim B, Gilmore K, et al. (2009) Methamphetamine induces dopamine D1 receptor-dependent endoplasmic reticulum stress-related molecular events in the rat striatum. PLoS One 4: e6092.
34. Andres ME, Burger C, Peral-Rubio MJ, Battaglioli E, Anderson ME, et al. (1999) CoREST: a functional corepressor required for regulation of neural-specific gene expression. Proc Natl Acad Sci U S A 96: 9873-9878.
35. Lunyak VV, Burgess R, Prefontaine GG, Nelson C, Sze SH, et al. (2002) Corepressor-dependent silencing of chromosomal regions encoding neuronal genes. Science 298: 1747-1752.
36. Bruce AW, Donaldson IJ, Wood IC, Yerbury SA, Sadowski MI, et al. (2004) Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci U S A 101: 10458-10463.
37. Hu Z, Yang B, Lu W, Zhou W, Zeng L, et al. (2008) HSPB2/MKBP, a novel and unique member of the small heat-shock protein family. J Neurosci Res 86: 2125-2133.
38. Suzuki A, Sugiyama Y, Hayashi Y, Nyu-i N, Yoshida M, et al. (1998) MKBP, a novel member of the small heat shock protein family, binds and activates the myotonic dystrophy protein kinase. J Cell Biol 140: 1113-1124.
39. Arrigo AP (2007) The cellular "networking" of mammalian Hsp27 and its functions in the control of protein folding, redox state and apoptosis. Adv Exp Med Biol 594: 14-26.
40. Sun Y, MacRae TH (2005) The small heat shock proteins and their role in human disease. Febs J 272: 2613-2627.
41. Nakagawa M, Tsujimoto N, Nakagawa H, Iwaki T, Fukumaki Y, et al. (2001) Association of HSPB2, a member of the small heat shock protein family, with mitochondria. Exp Cell Res 271: 161-168.
42. Morrison LE, Whittaker RJ, Klepper RE, Wawrousek EF, Glembotski CC (2004) Roles for alphaB-crystallin and HSPB2 in protecting the myocardium from ischemia-reperfusion-induced damage in a KO mouse model. Am J Physiol Heart Circ Physiol 286: H847-855.
43. Oliver C, Eskay RL, Ben-Jonathan N, Porter JC (1974) Distribution and concentration of TRH in the rat brain. Endocrinology 95: 540-546.
44. Kalivas PW, Stanley D, Prange AJ Jr (1987) Interaction between thyrotropin-releasing hormone and the mesolimbic dopamine system. Neuropharmacology 26: 33-38.
45. Engber TM, Manaker S, Kreider MS, Winokur A (1985) Intraventricular 6-hydroxydopamine increases thyrotropin-releasing hormone (TRH) content in regions of rat brain. Regul Pept 12: 51-57.
46. Ishihara H, Shibasaki Y, Kizuki N, Wada T, Yazaki Y, et al. (1998) Type I phosphatidylinositol-4-phosphate 5-kinases. Cloning of the third isoform and deletion/substitution analysis of members of this novel lipid kinase family. J Biol Chem 273: 8741-8748.
47. Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, et al. (2001) Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 291: 1051-1055.
48. Itoh T, Koshiba S, Kigawa T, Kikuchi A, Yokoyama S, et al. (2001) Role of the ENTH domain in phosphatidylinositol-4,5-bisphosphate binding and endocytosis. Science 291: 1047-1051.
49. Mao YS, Yin HL (2007) Regulation of the actin cytoskeleton by phosphatidylinositol 4-phosphate 5 kinases. Pflugers Arch 455: 5-18.
50. Wang YJ, Li WH, Wang J, Xu K, Dong P, et al. (2004) Critical role of PIP5KI{gamma}87 in InsP3-mediated Ca(2+) signaling. J Cell Biol 167: 1005-1010.
51. Oude Weernink PA, Schmidt M, Jakobs KH (2004) Regulation and cellular roles of phosphoinositide 5-kinases. Eur J Pharmacol 500: 87-99.
52. Ye K, Ahn JY (2008) Nuclear phosphoinositide signaling. Front Biosci 13: 540-548.
53. Oude Weernink PA, Han L, Jakobs KH, Schmidt M (2007) Dynamic phospholipid signaling by G protein-coupled receptors. Biochim Biophys Acta 1768: 888-900.
54. Wenk MR, Pellegrini L, Klenchin VA, Di Paolo G, Chang S, et al. (2001) PIP kinase Igamma is the major PI(4,5)P(2) synthesizing enzyme at the synapse. Neuron 32: 79-88.
55. Wang Y, Lian L, Golden JA, Morrisey EE, Abrams CS (2007) PIP5KI gamma is required for cardiovascular and neuronal development. Proc Natl Acad Sci U S A 104: 11748-11753.
56. Paul S, Lombroso PJ (2003) Receptor and nonreceptor protein tyrosine phosphatases in the nervous system. Cell Mol Life Sci 60: 2465-2482.
57. Stoker AW (2005) Protein tyrosine phosphatases and signalling. J Endocrinol 185: 19-33.
58. Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7: 833-846.
59. Brady-Kalnay SM, Flint AJ, Tonks NK (1993) Homophilic binding of PTP mu, a receptor-type protein tyrosine phosphatase, can mediate cell-cell aggregation. J Cell Biol 122: 961-972.
60. Brady-Kalnay SM, Rimm DL, Tonks NK (1995) Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo. J Cell Biol 130: 977-986.
61. Arikkath J, Reichardt LF (2008) Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. Trends Neurosci 31: 487-494.
62. Robinson TE, Kolb B (2004) Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology 47 Suppl 1: 33-46.
63. Rajeevan MS, Vernon SD, Taysavang N, Unger ER (2001) Validation of array-based gene expression profiles by real-time (kinetic) RT-PCR. J Mol Diagn 3: 26-31.
64. Cadet JL, Krasnova IN (2009) Cellular and molecular neurobiology of brain preconditioning. Mol Neurobiol 39: 50-61.
65. Truettner J, Busto R, Zhao W, Ginsberg MD, Perez-Pinzon MA (2002) Effect of ischemic preconditioning on the expression of putative neuroprotective genes in the rat brain. Brain Res Mol Brain Res 103: 106-115.
66. Jayanthi S, McCoy MT, Ladenheim B, Cadet JL (2002) Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. Mol Pharmacol 61: 1124-1131.
67. Thomas DM, Francescutti-Verbeem DM, Liu X, Kuhn DM (2004) Identification of differentially regulated transcripts in mouse striatum following methamphetamine treatment - an oligonucleotide microarray approach. J Neurochem 88: 380-393.
68. Lee TH, Yang JT, Ko YS, Kato H, Itoyama Y, et al. (2008) Influence of ischemic preconditioning on levels of nerve growth factor, brain-derived neurotrophic factor and their high-affinity receptors in hippocampus following forebrain ischemia. Brain Res 1187: 1-11.
69. Marini AM, Jiang X, Wu X, Pan H, Guo Z, et al. (2007) Preconditioning and neurotrophins: a model for brain adaptation to seizures, ischemia and other stressful stimuli. Amino Acids 32: 299-304.
70. Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, et al. (2007) Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci 27: 8816-8825.
71. Cass WA (1996) GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J Neurosci 16: 8132-8139.
72. Cass WA, Peters LE, Harned ME, Seroogy KB (2006) Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine. Ann N Y Acad Sci 1074: 272-281.
73. Canudas AM, Pezzi S, Canals JM, Pallas M, Alberch J (2005) Endogenous brain-derived neurotrophic factor protects dopaminergic nigral neurons against transneuronal degeneration induced by striatal excitotoxic injury. Brain Res Mol Brain Res 134: 147-154.
74. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132.
75. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, et al. (1994) Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342: 321-334.
76. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, et al. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373: 335-339.
77. Bigdeli MR (2009) Preconditioning with prolonged normobaric hyperoxia induces ischemic tolerance partly by upregulation of antioxidant enzymes in rat brain tissue. Brain Res 1260: 47-54.
78. Glantz L, Avramovich A, Trembovler V, Gurvitz V, Kohen R, et al. (2005) Ischemic preconditioning increases antioxidants in the brain and peripheral organs after cerebral ischemia. Exp Neurol 192: 117-124.
79. Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res 11: 183-202.
80. Cadet JL, Sheng P, Ali S, Rothman R, Carlson E, et al. (1994) Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J Neurochem 62: 380-383.
81. Cadet JL, Ordonez SV, Ordonez JV (1997) Methamphetamine induces apoptosis in immortalized neural cells: protection by the proto-oncogene, bcl-2. Synapse 25: 176-184.
82. Jayanthi S, Ladenheim B, Cadet JL (1998) Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice. Ann N Y Acad Sci 844: 92-102.
83. Huang YN, Wu CH, Lin TC, Wang JY (2009) Methamphetamine induces heme oxygenase-1 expression in cortical neurons and glia to prevent its toxicity. Toxicol Appl Pharmacol. July 2.
84. Kim YT, Lee SW, Kwon DH, Seo JH, Ahn BC, et al. (2009) Dose-dependent frontal hypometabolism on FDG-PET in methamphetamine abusers. J Psychiatr Res 43: 1166-70.
85. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, et al. (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61: 73-84.
86. Kamphuis W, Dijk F, Bergen AA (2007) Ischemic preconditioning alters the pattern of gene expression changes in response to full retinal ischemia. Mol Vis 13: 1892-1901.
87. Reamon-Buettner SM, Mutschler V, Borlak J (2008) The next innovation cycle in toxicogenomics: environmental epigenetics. Mutat Res 659: 158-165.
88. Tang WY, Ho SM (2007) Epigenetic alterations and imprinting in origins of disease. Rev Endocr Metab Disord 8: 173-182.
89. Guillemin R, Yamazaki E, Gard DA, Jutisz M, Sakiz E (1963) In Vitro secretion of Thyrotropin (Tsh): Stimulation by a Hypothalamic Peptide (Trf). Endocrinology 73: 564-572.
90. Kamath J, Yarbrough GG, Prange AJ, Jr., Winokur A (2009) The thyrotropin-releasing hormone (TRH)-immune system homeostatic hypothesis. Pharmacol Ther 121: 20-28.
91. Lechan RM, Fekete C (2006) The TRH neuron: a hypothalamic integrator of energy metabolism. Prog Brain Res 153: 209-235.
92. Faden AI, Jacobs TP, Holaday JW (1981) Thyrotropin-releasing hormone improves neurologic recovery after spinal trauma in cats. N Engl J Med 305: 1063-1067.
93. Faden AI, Fox GB, Fan L, Araldi GL, Qiao L, et al. (1999) Novel TRH analog improves motor and cognitive recovery after traumatic brain injury in rodents. Am J Physiol 277: R1196-1204.
94. Shrewsbury-Gee J, Lye RH, Latham A, Slater P (1988) The effects of TRH analogues on cerebral ischaemia produced by middle cerebral artery occlusion in the rat. Exp Brain Res 70: 342-350.
95. Yamamoto M, Shimizu M, Okamiya H (1990) Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia. Eur J Pharmacol 181: 207-214.
96. Pizzi M, Boroni F, Benarese M, Moraitis C, Memo M, et al. (1999) Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. Eur J Pharmacol 370: 133-137.
97. Jaworska-Feil L, Kajta M, Budziszewska B, Leskiewicz M, Lason W (2001) Protective effects of TRH and its stable analogue, RGH-2202, on kainate-induced seizures and neurotoxicity in rodents. Epilepsy Res 43: 67-73.
98. Veronesi MC, Yard M, Jackson J, Lahiri DK, Kubek MJ (2007) An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro. Brain Res 1128: 79-85.
99. Obrenovitch TP (2008) Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev 88: 211-247.
100. Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24: 677-736.
101. Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9: 580-586.
102. Wu X, Chen PS, Dallas S, Wilson B, Block ML, et al. (2008) Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 11: 1123-1134.
103. Martinowich K, Hattori D, Wu H, Fouse S, He F, et al. (2003) DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science 302: 890-893.
104. Dennis KE, Levitt P (2005) Regional expression of brain derived neurotrophic factor (BDNF) is correlated with dynamic patterns of promoter methylation in the developing mouse forebrain. Brain Res Mol Brain Res 140: 1-9.
105. Dong M, Wu Y, Fan Y, Xu M, Zhang J (2006) c-fos modulates brain-derived neurotrophic factor mRNA expression in mouse hippocampal CA3 and dentate gyrus neurons. Neurosci Lett 400: 177-180.
106. Zhang J, Zhang D, McQuade JS, Behbehani M, Tsien JZ, et al. (2002) c-fos regulates neuronal excitability and survival. Nat Genet 30: 416-420.
107. Engele J, Schilling K (1996) Growth factor-induced c-fos expression defines distinct subsets of midbrain dopaminergic neurons. Neuroscience 73: 397-406.
108. Deng X, Ladenheim B, Tsao LI, Cadet JL (1999) Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity. J Neurosci 19: 10107-10115.
109. Guerra-Crespo M, Ubieta R, Joseph-Bravo P, Charli JL, Perez-Martinez L (2001) BDNF increases the early expression of TRH mRNA in fetal TrkB+hypothalamic neurons in primary culture. Eur J Neurosci 14: 483-494.
110. Ubieta R, Uribe RM, Gonzalez JA, Garcia-Vazquez A, Perez-Monter C, et al. (2007) BDNF up-regulates pre-pro-TRH mRNA expression in the fetal/ neonatal paraventricular nucleus of the hypothalamus. Properties of the transduction pathway. Brain Res 1174: 28-38.
111. Berry A, Greco A, Giorgio M, Pelicci PG, de Kloet R, et al. (2008) Deletion of the lifespan determinant p66(Shc) improves performance in a spatial memory task, decreases levels of oxidative stress markers in the hippocampus and increases levels of the neurotrophin BDNF in adult mice. Exp Gerontol 43: 200-208.
112. Siamilis S, Jakus J, Nyakas C, Costa A, Mihalik B, et al. (2009) The effect of exercise and oxidant-antioxidant intervention on the levels of neurotrophins and free radicals in spinal cord of rats. Spinal Cord 47: 453-457.
113. Yamagata T, Satoh T, Ishikawa Y, Nakatani A, Yamada M, et al. (1999) Brain-derived neurotropic factor prevents superoxide anion-induced death of PC12h cells stably expressing TrkB receptor via modulation of reactive oxygen species. Neurosci Res 35: 9-17.
114. Cadet JL, Brannock C (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 32: 117-131.
115. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658.
116. De Vito MJ, Wagner GC (1989) Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology 28: 1145-1150.
117. Hirata H, Ladenheim B, Carlson E, Epstein C, Cadet JL (1996) Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res 714: 95-103.
118. Kuhn DM, Francescutti-Verbeem DM, Thomas DM (2006) Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci 1074: 31-41.
119. Miyazaki I, Asanuma M, Diaz-Corrales FJ, Fukuda M, Kitaichi K, et al. (2006) Methamphetamine-induced dopaminergic neurotoxicity is regulated by quinone-formation-related molecules. Faseb J 20: 571-573.
120. Chinta SJ, Andersen JK (2005) Dopaminergic neurons. Int J Biochem Cell Biol 37: 942-946.
121. Calabrese V, Stella AM, Butterfield DA, Scapagnini G (2004) Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal 6: 895-913.
122. Li C, Hossieny P, Wu BJ, Qawasmeh A, Beck K, et al. (2007) Pharmacologic induction of heme oxygenase-1. Antioxid Redox Signal 9: 2227-2239.
123. Li Q, Li J, Zhang L, Wang B, Xiong L (2007) Preconditioning with hyperbaric oxygen induces tolerance against oxidative injury via increased expression of heme oxygenase-1 in primary cultured spinal cord neurons. Life Sci 80: 1087-1093.
124. Li Q, Zhu Y, Jiang H, Xu H, Liu H (2008) Up-regulation of heme oxygenase-1 by isoflurane preconditioning during tolerance against neuronal injury induced by oxygen glucose deprivation. Acta Biochim Biophys Sin (Shanghai) 40: 803-810.
125. Hung SY, Liou HC, Kang KH, Wu RM, Wen CC, et al. (2008) Overexpression of heme oxygenase-1 protects dopaminergic neurons against 1-methyl-4-phenylpyridinium-induced neurotoxicity. Mol Pharmacol 74: 1564-1575.
126. Domesick VB (1988) Neuroanatomical organization of dopamine neurons in the ventral tegmental area. Ann N Y Acad Sci 537: 10-26.
127. Lindvall O, Bjorklund A (1978) Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 19: 1-23.
128. Krasnova IN, Bychkov ER, Lioudyno VI, Zubareva OE, Dambinova SA (2000) Intracerebroventricular administration of substance P increases dopamine content in the brain of 6-hydroxydopamine-lesioned rats. Neuroscience 95: 113-117.